Overview

Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer

Status:
Terminated

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

This study will evaluate progression free survival (PFS), overall survival (OS), objective response rate (ORR), duration of response, and safety of motesanib (AMG706) in combination with paclitaxel and carboplatin compared to placebo in combination with paclitaxel and carboplatin.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Motesanib diphosphate
Niacinamide
Paclitaxel